Grail, Inc. (GRAL) Stock Price & Analysis
Grail, Inc. (GRAL) fell 1.54% to USD 79.1 as of September 9, 2026 at 01:32 UTC, according to Nexqual real-time market data.
GRAL last closed at USD 79.1; the session ranged USD 78.85–81.71 on volume of 693,176 shares. Market capitalization is —, with a 52-week range of USD 35.39–118.84 (NMS). Source: Nexqual, September 9, 2026 at 01:32 UTC.
Key Statistics (as of September 9, 2026 at 01:32 UTC)
| Price | USD 79.1 |
|---|---|
| Change | ▼ 1.54% (down) |
| Previous Close | USD 79.1 |
| Open | USD 79.1 |
| Day Range | USD 78.85 – 81.71 |
| 52-Week Range | USD 35.39 – 118.84 |
| Volume | 693,176 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (GRAL)
Nexqual's technical model rates GRAL "STRONG BUY" based on 5 bullish and 0 bearish signals across 126 daily candles, as of September 9, 2026 at 01:32 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.24 (neutral) |
| vs SMA50 | Above (USD 72.47) |
| MACD | 2.88 (positive) |
From Grail, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- The law included certain standards, including that Centers for Medicare and Medicaid Services ("CMS") would establish coverage through a national coverage determination ("NCD") process under "reasonable and necessary" evidentiary requirements.
- We can leverage our proprietary platform for additional applications, including our precision oncology portfolio.
- The commercial opportunity for Galleri is significant, with more than 300 million individuals globally over the age of 50 (our intended use population), including more than 100 million individuals in the United States.
- Our proprietary targeted methylation platform, as well as our growing body of clinical and real-world data, have provided us with unique insights into cancer biology that enable development of products beyond asymptomatic screening.
Partnerships
- We have also begun entering select international markets through distributor partners, including Israel and Canada, and intend to enter South Korea through our partnership with Samsung.
- Under our agreement with the NHS, these results have met certain success criteria and missed others.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| WGS | GeneDx Holdings Corp. | USD 85.87 | ▼ 1.74% |
| RVMD | Revolution Medicines, Inc. | USD 207.32 | ▼ 1.68% |
| NTRA | Natera, Inc. | USD 324.14 | ▼ 1.08% |
| GH | Guardant Health, Inc. | USD 160.98 | ▼ 0.04% |
| GPCR | Structure Therapeutics Inc. | USD 40.38 | ▼ 14.7% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 01:32 UTC. This page is informational and not investment advice.